Through a comprehensive analysis of a publicly available database, we revealed that CD318 has divergent immunological consequences, correlating with a favorable prognosis in colorectal cancer (COAD) but unfavorable outcomes in cervical, lung, and pancreatic adenocarcinomas. The gene discussed is CDCP1; the disease is colorectal cancer.